ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tisotumab vedotin

Also written as “Tisotumab Vedotin”, “TIVDAK” and “Tisotumab Vedotin (HuMax-TF-ADC)”.

Its studies are mostly in Uterine Cervical Neoplasms · Ovarian Neoplasms · Colorectal Neoplasms · Neoplasm Metastasis, led by 3 companies.

Drug pageTisotumab vedotin: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 15, 202511 company-led studies, 2 open or runningNext primary completion: Dec 13, 2028 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizerits history only92 open or runningphase 4since Apr 15, 2025Nov 14, 2013Dec 13, 2028phase 4 · NCT06952660
Genmab10 open or runningphase 2since Mar 29, 2019Mar 29, 2019none ahead
Zai Labits history only10 open or runningphase 1since Apr 27, 2023Apr 27, 2023none ahead

Also a collaborator on its studies: Merck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Genmab only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2015Named tisotumab vedotinINNProposed as its International Nonproprietary Name in WHO's List 113
  2. Mar 29, 2019First study: phase 2 study in Uterine Cervical NeoplasmsFirst studyNCT03913741 · 23 enrolled · Japan

TargetBeta

F3 →read by rule
“An antibody-drug conjugate (ADC) comprised of tisotumab, a monoclonal antibody against human tissue factor (TF) covalently coupled, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and potent microtubule disrupting agent, ”NCIt, by rule
“Coagulation factor III binding agent”ChEMBL 37, by rule

Other programs on F3

ProgramCompanyFurthest phaseStudies
Anti-TF/TOP1i Antibody-drug Conjugate XNW28012ruleEvopoint Biosciencesphase 33
Anti-TF Antibody-drug Conjugate MRG004Arulelepu-biopharma-co-ltdphase 32
SHR-4375Jiangsu HengRui Medicinephase 22
Anti-TF/TOP1i Antibody-drug Conjugate XB371ruleExelixisphase 11
Anti-TF/Exatecan Antibody-drug Conjugate STRO-004rulesutro-biopharma-incphase 11

Studies

The one study Genmab leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03913741Uterine Cervical Neoplasms · Japan2CompletedAug 14, 202023

How it is read

Names in the registry

  • “tisotumab vedotin”, 5 entries
  • “Tisotumab Vedotin”, 3 entries
  • “TIVDAK”, 1 entry
  • “Tisotumab Vedotin (HuMax-TF-ADC)”, 1 entry
  • “Tisotumab vedotin (HuMax-TF-ADC)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.